Mode
Text Size
Log in / Sign up

Individual patient data meta-analysis links myocardial injury categories to cardiovascular event riskHeart Attack Risk: New Classification Changes Everything for Patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider that all myocardial injury categories increase cardiovascular event risk, but interpret Type 2 MI risk cautiously due to competing noncardiovascular death.

This is an individual patient-level data meta-analysis of prospective studies from 9 countries, synthesizing data from 120,734 patients with myocardial injury and infarction classified according to the Universal Definition. The population included patients across the spectrum of myocardial injury, categorized into Type 1 MI, Type 2 MI, Acute Myocardial Injury, and Chronic Myocardial Injury. The comparator was patients without myocardial injury. The analysis had a minimum follow-up of 1 year.

The intervention or exposure was the classification into specific myocardial injury and infarction categories. The primary outcome was major adverse cardiovascular events (MACE), defined as MI or cardiovascular death. Key secondary outcomes included noncardiovascular death.

For the primary outcome, the MACE rate was 55.2 per 1,000 patient-years for Type 1 MI (n=11,298) versus 51.7 per 1,000 patient-years for Type 2 MI (n=3,609). The risk of MACE for Type 1 MI versus no MI was a subdistribution HR of 4.82 (95% CI: 3.55-6.57), indicating increased risk. The risk of MACE for Type 2 MI versus no MI was a subdistribution HR of 3.36 (95% CI: 2.92-3.86), also indicating increased risk. The MACE rate for Acute Myocardial Injury was 47.1 per 1,000 patient-years (n=5,864) versus 44.9 per 1,000 patient-years for Chronic Myocardial Injury (n=5,625). The risk of MACE for Acute Myocardial Injury versus no MI was a subdistribution HR of 3.24 (95% CI: 2.41-4.36), and for Chronic Myocardial Injury versus no MI, it was a subdistribution HR of 3.03 (95% CI: 2.53-3.62), both indicating increased risk.

For key secondary outcomes, the noncardiovascular death rate was 25.7 per 1,000 patient-years for Type 1 MI versus 60.1 per 1,000 patient-years for Type 2 MI. The noncardiovascular death rate for Acute Myocardial Injury was 67.0 per 1,000 patient-years versus 46.9 per 1,000 patient-years for Chronic Myocardial Injury.

Safety and tolerability findings were not reported in the input data, including adverse events, serious adverse events, and discontinuations.

These results can be compared to prior landmark studies in this therapeutic area, which have generally shown that myocardial injury is associated with adverse outcomes. This meta-analysis provides individual patient-level data across multiple prospective studies, offering a more granular view of risk by injury category. The finding of a substantially greater competing risk of noncardiovascular death in Type 2 MI is a key distinction from some prior analyses.

Key methodological limitations include the competing risk of noncardiovascular death, which affects risk interpretation in Type 2 MI, as noted in the limitations. The analysis is observational, and the authors caution against inferring causation from association. Potential biases inherent in meta-analyses of prospective studies, such as heterogeneity in study protocols and definitions, are not detailed but should be considered.

Clinically, these results imply that all patients with myocardial injury and infarction are at increased risk of future cardiovascular events. For Type 2 MI, the apparent risk is reduced by a substantially greater competing risk of noncardiovascular death, which should inform risk stratification and management decisions. Practice relevance emphasizes that clinicians should consider the full risk profile, including noncardiovascular mortality.

Unanswered questions remain regarding the mechanisms driving the increased risk in different injury categories, optimal management strategies tailored to each category, and the impact of interventions on these outcomes. Further research is needed to address these gaps.

Why the Type of Heart Damage Matters

Heart attacks happen when blood flow to your heart gets blocked. But doctors now know there are different reasons this happens.

Type 1 heart attacks occur when a blood clot forms in a narrowed artery. This is what most people picture when they think "heart attack."

Type 2 heart attacks happen when your heart needs more oxygen than it's getting. This can be caused by severe infection, blood loss, or a very fast heart rate.

There's also myocardial injury. That's when heart cells die but not from a classic heart attack. It can be acute (sudden) or chronic (ongoing).

The old way of thinking treated all heart damage the same. But here's the twist: the new research shows these categories predict very different futures.

A New Way to Look at Risk

The study tracked 120,734 patients from 9 countries. Researchers followed them for at least one year after their initial hospital visit.

What they found surprised many doctors.

Patients with type 1 heart attacks had the highest risk of having another heart attack or dying from heart disease. Their rate was 55.2 events per 1,000 patient-years.

But patients with type 2 heart attacks had a different story. Their heart-related risk was slightly lower at 51.7 events per 1,000 patient-years.

But here's what changes everything: type 2 patients were much more likely to die from non-heart causes.

The Hidden Danger in Type 2 Heart Attacks

The study found that patients with type 2 heart attacks died from non-cardiovascular causes at a rate of 60.1 per 1,000 patient-years. That's more than double the rate for type 1 patients (25.7 per 1,000 patient-years).

What does this mean? If you have a type 2 heart attack, your biggest threat may not be another heart attack. It may be the underlying condition that caused it in the first place.

Think of it this way. A type 1 heart attack is like a traffic jam in a specific artery. Fix that jam, and the road is clear.

A type 2 heart attack is like a car that's overheating because the engine is failing. You can cool it down, but the engine problem remains.

What This Means for Patients

This study changes how doctors should think about your risk.

If you have a type 1 heart attack, your doctor will focus on preventing future clots. You'll likely get blood thinners, statins, and maybe a stent.

If you have a type 2 heart attack, your doctor needs to look deeper. What caused your heart to need more oxygen? Is it an infection? Anemia? A thyroid problem?

The study also looked at patients with myocardial injury. These patients had similar heart risks to type 2 patients. But their non-heart death rates were also high.

The Catch

This research is based on data from 17 studies. That's a lot of information. But it's still observational. That means it shows patterns, not proof.

The researchers note that there was high variation between studies for some results. This means the findings may not apply to every patient group.

Also, the study used data from 2007 to 2025. Treatment has changed during that time. Newer treatments might change these risk patterns.

What Happens Next

Doctors are already using the Universal Definition to classify heart attacks. But this study shows they need to use it more carefully.

The next step is for hospitals to create separate treatment paths for each type of heart damage. Type 1 patients need aggressive heart prevention. Type 2 patients need a full workup for other health problems.

Clinical trials are needed to test whether different treatments improve outcomes for each group. That takes time.

For now, if you've had a heart attack, ask your doctor which type you had. It could change how you think about your future health.

Study Details

Study typeMeta analysis
Sample sizen = 11,298
EvidenceLevel 1
Follow-up12.0 mo
PublishedMay 2026
View Original Abstract ↓
BACKGROUND: The Universal Definition classifies myocardial infarction (MI) by etiology, but its prognostic implications are uncertain. OBJECTIVES: The goal was to compare the rate and risk of recurrent MI or cardiovascular death among patients with myocardial injury and infarction classified according to the Universal Definition. METHODS: A systematic search of MEDLINE, EMBASE, Central, and Web of Science from January 1, 2007 to July 1, 2025 was performed to identify prospective studies where cardiac troponin was measured for suspected acute coronary syndrome, diagnoses were adjudicated using the Universal Definition, and both MI and cause-specific mortality were reported at a minimum of 1 year. Subdistribution HRs were derived to account for the competing risk of noncardiovascular death. Meta-analysis was performed with random-effects models. The primary outcome was major adverse cardiovascular events (MACE), defined as MI or cardiovascular death. The secondary outcome was noncardiovascular death. RESULTS: We identified 17 studies of 9 cohorts from 9 countries, with individual patient-level data available in 8 cohorts. Among 120,734 patients (median age: 61.0 years; 45.8% women), type 1 MI occurred in 9.4% (n = 11,298), type 2 MI in 3.0% (n = 3,609), acute myocardial injury in 4.9% (n = 5,864), and chronic myocardial injury in 4.7% (n = 5,625). In patients with type 1 and type 2 MI, the MACE rate was 55.2 and 51.7 per 1,000 patient-years and the noncardiovascular death rate was 25.7 and 60.1 per 1,000 patient-years, respectively. Compared with those without myocardial injury, the risk of MACE (subdistribution HR) was 4.82 (95% CI: 3.55-6.57; I = 84%) and 3.36 (95% CI: 2.92-3.86; I = 0%), respectively. In patients with acute and chronic myocardial injury, the MACE rate was 47.1 and 44.9 per 1,000 patient-years and the noncardiovascular death rate was 67.0 and 46.9 per 1,000 patient-years, respectively. The risk of MACE was 3.24 (95% CI: 2.41-4.36; I = 59%) and 3.03 (95% CI: 2.53-3.62; I = 20%), respectively. CONCLUSIONS: All patients with myocardial injury and infarction are at increased risk of future cardiovascular events. However, in type 2 MI, this apparent risk is reduced by a substantially greater competing risk of noncardiovascular death. (PROSPERO Registration: CRD42023464836).
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.